I know chlamydia is just a bonus but if it is 75% and Gono is 90% than a Macrolide oral therapy to the community should/could get a 20 point pop IMHO. It may settle up only 15 for the day but Cemp will rocket for sure. Many upgrades will follow for 3 days. New trading ranges and buy out numbers will be discussed. If you think up a quick 6 bucks is a time to sell Cemp…………I think it is just the beginning. Cheers.
Gono results are a HUGE deal. A Macrolide to disperse to the community setting for Gono would be a "Cash Cow" for the owner of Soli. If the results are stellar in this indication there will be multiple suitors for sure. IV is basically a slam dunk as the oral already proved to be highly efficient. So, a nice tasty offer after the positive Gono results would not shock me in the least. $80 buy out sounds right if before 2016. $115 if by the end of 2016.
Nice job explaining Soli/Cemp in detail. We are reaching the finish line ( IV is slam dunk)and with the possibility of gono news popping on the news wire sooner than expected should keep the shorts on the defensive. Gono news should result in an 8 point or more pop. It will be a nice Christmas. Join me and buy the biggest tree in your town. Cheers
I wouldn't bet the farm but looking at the chart the 33.38 today may be the lowest Cemp ever goes again. With the ETF,s in control I only glance at charts but it will be fun to see if the right angle pattern holds as we near Gono results. I , myself would be glad to see 29 on a market crash , I would then happily bet the farm.
It makes perfect sense. If you understand the antibiotic field. I will not explain it to you today but I will say that Cemp has the bigger upside in PPS in the end and will get the bigger buy out $$$ as well. Stifel gets it and other analysts will up their numbers as well. I think even 57 is low but even that number is 22 points higher from here. I think TTPH is getting a buy out sooner and it is getting priced in. Their drug will have a big price tag and will be a life saver in hospital.
Click on the yearly chart and maybe listen to the last conference call. The chart is sweet. The Soli data is sweet. Prabavathi is sweet. This should put a spring in your step.
Went from over sold to over bought pretty fast. IBB hit hard today.The cream always rises to the top though. I have been buying in the low 30's for my trading account and selling in high 30's until the middle of July. Cemp PPS will move up before and after the Gono news so I will be all in and done trading Cemp in July.
Stephen Willey was actually one of the guys that under appreciated Cemp . He also downgraded ISIS 4 months ago. Not a good call. Nice to see that the light bulb finally went on for him for Cemp.
I agree. Cemp will break out. TTPH has already broken out. I feel bad for those that sold on the last 2 drops. We did our best to relieve any concerns on this board. The big boys stole a lot of shares on the cheap ( me included). The week hands are all gone. Their PPS targets were crazy low and now they are ready to up them. A buy out will be a huge premium to todays PPS. The first hulkian macrolide in 25 yrs. Cemp really was a " no brainer". They don't come around that often. Cheers to all.
COPD? Experiencing corticosteroid insensitivity ?
A combination of SOL and Dex inhibited neutrophilia by over 50%.
STD? No problem…..
The MIC of solithromycin was correlated with mutations in the 23S rRNA gene and in the genes encoding ribosomal proteins L4 and L22. The in vitro results showed that solithromycin has activity against M. genitalium superior to that of other macrolides, doxycycline, and fluoroquinolones.
Nice find. my favorite Abstract is:
Solithromycin, a next-generation macrolide and novel fluoroketolide, was tested against a 2012 collection of serotyped U.S. macrolide-resistant Streptococcus pneumoniae isolates associated with community-acquired bacterial pneumonia (CABP). Against all 272 isolates, solithromycin demonstrated high potency (MIC50/90, 0.06/0.25 μg/ml), and it inhibited all strains at MICs of ≤0.5 μg/ml, including the two most prevalent macrolide-resistant serotypes (19A and 35B). These data support the continued clinical development of solithromycin for the treatment of multidrug-resistant CABP.
Every sell off puts shares in much stronger hands. The chart lines up nicely with the coming catalysts . I see 35 as the mendosa line . It may never drop below it ever again once it rises above it. A huge bio sell off would be the only problem but I would just buy more. Like I did at 32 two days ago. Enjoy the summer.
I love Prabha and trust her greatly but if she has a fault it is that she has been off on her timing of a few catalysts. Im not really complaining as there were huge sell offs of the PPS in the past due to these slight delays which I was happy to take huge advantage of. If we truly have all the Soli IV data at the end on 2015 then buying heavy on any big dip due to this news bite would be like "money in the bank." Gono should be on schedule and could pop the PPS in a big way as well.
um….those sectors are wayyyy over bought and may be hitting highs that will never be seen again for a cple of years. Cemp? Well….. it is way over sold and has Soli…..an already proven billion dollar drug that is being washed out with all the small,unproven ,speculative bio companys. The investors here are to smart for your pumping. And for what its worth, I have 95% of my $$$$ in Cemp and sleep very well thank you.
Funds are waiting,drooling,praying for a pull back in Cemp. Cemp gets bid up in a fury when it visits the low 30's. I suggest that everyone else does the same. Buy a car for the wife for Christmas instead of a dish washer. Cheers.
A Secondary is considered good news when the drug has been proven. Its a guaranteed investment in a soon to be successful launch. The PPS will almost always goes up in this scenario.
Both will be the new 1000 lb gorilla in their indications. Soli will have massive unit sales in community. TTPH will have very high pricing for IV in hospital. Soli IV will get its share of high $$ pricing also. I prefer Cemp. Both most likely will be sold at nice premiums.